Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On April 18, 2022, Mustang Bio, Inc. (the "Company") appointed Eliot M. Lurier
as the Company's Interim Chief Financial Officer. Mr. Lurier provides consulting
services to the Company pursuant to a consulting agreement (the "Danforth
Consulting Agreement") between the Company and Danforth Advisors, LLC
("Danforth") and receives no compensation directly from the Company.
Mr. Lurier, age 63, has served as a consultant to several companies through
Danforth, an advisory firm that provides operational and strategic support
services to life science companies. Prior to joining Danforth, from September
2014 to December 2020, Mr. Lurier was Chief Financial Officer of the Joslin
Diabetes Center, Inc., a preeminent diabetes research, clinical care, and
education organization. Prior to this, Mr. Lurier served as Chief Financial
Officer for a wide variety of public and private pharmaceutical companies. Mr.
Lurier holds a B.S. in Accounting from Syracuse University and is a Certified
Public Accountant in Massachusetts.
No family relationships exist between Mr. Lurier and any of the Company's
directors or executive officers. Other than the Danforth Consulting Agreement,
there are no arrangements between Mr. Lurier and any other person pursuant to
which Mr. Lurier was selected as the Company's principal financial officer, nor
are there any transactions to which the Company is or was a participant and in
which Mr. Lurier has a material interest subject to disclosure under Item 404(a)
of Regulation S-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is furnished herewith:
Exhibit
Number Description
99.1 Consulting Agreement by and between Mustang Bio, Inc. and Danforth
Advisors, LLC dated March 17, 2022.
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained
in Exhibit 101)
© Edgar Online, source Glimpses